2013-09-10 10:57:08 - Fast Market Research recommends "Bladder Cancer - Pipeline Review, H2 2013" from Global Markets Direct, now available
Global Markets Direct's, 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Bladder Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
* A snapshot of the global therapeutic scenario for Bladder Cancer.
* A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Full Report Details at
- www.fastmr.com/prod/675196_bladder_cancer_pipeline_review_h2_201 ..
Reasons to Get this Report
* Identify and understand important and diverse types of therapeutics under development for Bladder Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: Shionogi & Co., Ltd., Eli Lilly and Company, Viralytics Ltd., GlaxoSmithKline plc, Seattle Genetics, Inc., Bioniche Life Sciences, Inc., Bavarian Nordic A/S, Biotest AG, Samyang Corporation, Eisai Co., Ltd., MDRNA, Inc., Taiho Pharmaceutical Co., Ltd., Advaxis, Inc., AEterna Zentaris Inc., Alnylam Pharmaceuticals, Inc, Oncogenex Pharmaceuticals, Inc., Sanochemia Pharmazeutika AG, PharmaGap Inc., Quest PharmaTech Inc., Med Discovery SA, Altor BioScience Corporation, Telormedix SA, Gene Signal International SA., Heat Biologics, Inc., MacroGenics, Inc., Innate Therapeutics Limited, Stemline Therapeutics, Inc., BioCancell Therapeutics, Inc., AndroScience Corporation, BIND Biosciences, Inc., PharmaMar, S.A., Targa Therapeutics Corp., Cytavis Biopharma GmbH, Polaris Group, Serometrix, LLC, Regulon Inc.
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Bladder Cancer Overview
An Overview of Pipeline Products for Bladder Cancer
Bladder Cancer Therapeutics under Development by Companies
Bladder Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Bladder Cancer Therapeutics - Products under Development by Companies
Bladder Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Bladder Cancer Therapeutics Development
Shionogi & Co., Ltd.
Eli Lilly and Company
Seattle Genetics, Inc.
Bioniche Life Sciences, Inc.
Bavarian Nordic A/S
Eisai Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
AEterna Zentaris Inc.
Alnylam Pharmaceuticals, Inc
Oncogenex Pharmaceuticals, Inc.
Sanochemia Pharmazeutika AG
Quest PharmaTech Inc.
Med Discovery SA
Altor BioScience Corporation
Gene Signal International SA.
Heat Biologics, Inc.
Innate Therapeutics Limited
Stemline Therapeutics, Inc.
BioCancell Therapeutics, Inc.
BIND Biosciences, Inc.
Targa Therapeutics Corp.
Cytavis Biopharma GmbH
Bladder Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
AEZS-108 - Drug Profile
apatorsen - Drug Profile
MDRG-01 - Drug Profile
MDP-01 - Drug Profile
paclitaxel-loaded polymeric micelle - Drug Profile
ramucirumab - Drug Profile
EN-3348 - Drug Profile
SL-601 - Drug Profile
PVP Hypericin - Drug Profile
BT-062 - Drug Profile
TMX-202 - Drug Profile
BC-819 - Drug Profile
BC-821 - Drug Profile
MDR-09521 - Drug Profile
GAP-107-B-8 - Drug Profile
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.